ArticleCurrent oncology (Toronto, Ont.)2023

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.

Raquel Wescott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.